Given that improper gluten breakdown may amplify immune responses and that this systematic review observed that microbial peptidases involved in gluten digestion are likely altered in CeD, NCGS, and FD, targeting gluten-degrading peptidases presents a potential therapeutic strategy for managing GRDs. Here, LAP3 is linked to Fabry disease.